PolyNovo (PNV) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
AGM opened with acknowledgment of global humanitarian impact and company pride, noting supply to 42 countries at FY2024 close.
Chairman introduced directors, executive team, and auditors, highlighting recent board retirements and new appointments.
Meeting logistics covered, including online participation, voting procedures, and Q&A moderation.
Financial performance review
Company reported profitability with strong margins and AUD 49 million cash at year-end.
Staff numbers increased from 218 to 270 over the year, reflecting rapid growth.
Revenue growth of 49% in the U.S., with global expansion driving further gains.
No specific financial guidance provided, but growth remains on budget.
Board and executive committee updates
Andrew Lumsden re-elected as director and audit committee chair, with his background in finance and public company leadership highlighted.
Remuneration Committee now chaired by Christine Emmanuel, with Ingrid Anderson leading HR.
Policy introduced requiring directors to hold shares equal to their annual fees within three years.
Formal skills matrix for directors implemented to identify and address board expertise gaps.
Latest events from PolyNovo
- Sales up 26% to AUD 68.2M, NovoSorb MTX up 195%, and U.S. PMA submission on track for FY26.PNV
H1 202620 Feb 2026 - Record revenue and profit with global sales momentum and strong margins.PNV
H2 202423 Jan 2026 - Revenue up 22.8% and net profit up 23.9% in 1H25, with strong global sales and new launches.PNV
H1 202511 Dec 2025 - Record 28.9% sales growth and 149.1% profit increase, fueled by global expansion.PNV
H2 202523 Nov 2025 - Record sales, strong cash flow, and global expansion drive continued growth.PNV
Investor Update18 Nov 2025 - Double-digit sales and profit growth, global expansion, and new leadership drive momentum.PNV
Investor Presentation17 Nov 2025 - Record sales, strong cash flow, and global expansion support a positive growth outlook.PNV
H2 2025 TU16 Nov 2025 - Strong growth, governance reforms, and leadership changes amid shareholder scrutiny.PNV
AGM 202528 Oct 2025 - FY24 revenue surged 57.5% as NovoSorb products gain global traction in wound care.PNV
Canaccord Genuity Growth Conference Presentation13 Jun 2025